Actively Recruiting
Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Led by Queen Mary Hospital, Hong Kong · Updated on 2024-10-18
40
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.
CONDITIONS
Official Title
Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or above, either males or females.
- Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.
- Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use
- Written informed consent obtained from patient
- Subjects are diagnosed with advanced non-small cell lung cancer
You will not qualify if you...
- Age below 18
- Patients who are allergic to, or contraindicated to topical timolol use
- Pregnant women or nursing mother
- Non-consenting patients
- Subjects are not diagnosed with advanced non-small cell lung cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Queen Mary Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
W
Wang Chun Kwok
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here